Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

Core Insights - Protara Therapeutics is on track to report interim results from approximately 25 six-month evaluable patients in the ADVANCED-2 trial in Q1 2026, focusing on BCG-Unresponsive patients [1][5] - The company has received Breakthrough Therapy and Fast Track designations for TARA-002 in lymphatic malformations (LMs), with a regulatory update expected in the first half of 2026 [1][4] - The first patient has been dosed in the THRIVE-3 registrational trial of IV Choline Chloride, with interim results anticipated in the second half of 2026 [1][7] - Protara completed a public offering of approximately $86 million, extending its cash runway into 2028 [1][8] Protara's Pipeline and Progress - The CEO emphasized the company's commitment to delivering transformative therapies for cancer and rare diseases, highlighting the promising clinical data for TARA-002 in non-muscle invasive bladder cancer (NMIBC) [2] - TARA-002 has shown meaningful and durable activity in BCG-Naïve NMIBC patients, with plans to provide an interim update on the registrational BCG-Unresponsive trial later this quarter [2][5] - Positive results from the Phase 2 STARBORN-1 trial of TARA-002 in LMs have led to FDA designations, with a regulatory update on the path to registration expected in H1 2026 [2][4] Clinical Trials and Manufacturing - Protara is evaluating subcutaneous dosing combined with intravesical dosing for TARA-002 in NMIBC patients, as well as exploring combination treatments [5] - TARA-002 has been selected for the FDA's CMC Development and Readiness Pilot Program, aimed at facilitating manufacturing development for therapies with compressed clinical timelines [6] Financial Update - The recent public offering of approximately $86 million is expected to support Protara's operations and extend its financial runway into 2028 [8]